Table 1.
Patient characteristics
| AR (+) | AR (−) | P‐value | |
|---|---|---|---|
| (n = 16) | (n = 30) | ||
| Gender | |||
| Male/female | 13/3 | 20/10 | 0.295 |
| Age | |||
| Median | 67 | 65.5 | 0.133 |
| Range | 56–85 | 36–80 | |
| PS | |||
| 0 | 9 | 17 | |
| 1 | 5 | 11 | 0.780 |
| 2 | 2 | 2 | |
| Extent of disease | |||
| Local advance | 0 | 3 | 0.191 |
| Metastasis | 16 | 27 | |
| The number of metastatic organ | |||
| 0 | 0 | 3 | |
| 1 | 4 | 15 | 0.119 |
| 2 | 9 | 8 | |
| ≥3 | 3 | 4 | |
| Histological type | |||
| Intestinal type | 2 | 6 | 0.523 |
| Diffuse type | 14 | 24 | |
| First line chemotherapy | |||
| S1 | 9 | 11 | |
| S1+CDDP | 2 | 8 | 0.373 |
| S1+PTX | 5 | 11 | |
CDDP, cisplatin; PTX, paclitaxel; PS, performance status; S1, oral tegafur, 5‐chloro‐2,4‐dihydropyrimidine and potassium oxonate.